Thomas R. Bauer
Experimental Transplantation and Immunology Branch, CCR
National Cancer Institute
United States of America
Born in Southwestern PA, but raised during my formative years in the suburbs of Los Angeles, I left SoCal for Indiana, where I received a B.S. in microbiology from the University of Notre Dame in 1985. Desiring warmer weather, I went to the University of Miami (Florida), where I received a Ph.D. in microbiology and immunology in 1992 studying human immunoglobulin lambda light chain genes. From there, I joined the laboratory of Dennis Hickstein in Seattle, where I was a postdoc and later acting instructor, working on LAD and CD18, and to my current position as staff scientist at the NCI. Dr. Bauer has been working for more than a decade towards gene therapy to treat a childhood immunodeficiency disease known as leukocyte adhesion deficiency (LAD). Patients with LAD have defects in their leukocyte integrin CD18 gene, which leads to defective leukocytes that are unable to adhere to and migrate to sites of bacterial infection. In dogs that have canine leukocyte adhesion deficiency (CLAD),
1) leukocyte adhesion deficiency (LAD), 2) canine leukocyte adhesion deficiency (CLAD), 3) gene transfer, 4) leukocytes, 5) Clinical Research, 6) Computational Biology, 7) Genetics and Genomics, 8) Molecular Biology and Biochemistry.